Additional Study Information: This is a research study to test the effects of VB-111 combined with Bevacizumab versus Bevacizumab alone on glioblastoma . This study will enroll 252 subjects age 18 years and older who have recurrent glioblastoma. All subjects will be randomly assigned in a 1:1 ratio to receive either VB-111 combined with Bevacizumab or Bevacizumab alone. Survival, tumor response, and tumor growth rate will be used to determine the effectiveness of each treatment. As the best treatment for patients with recurrent glioblastoma is not known, this study may help identify an effective treatment with limited negative side effects.